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Background: To assess the value of Tiam1 in predicting lymph node metastasis and survival after curative resection
in patients with lung adenocarcinoma.
Methods: Immunohistochemical staining for Tiam1 was performed on 98 adenocarcinoma and 30 normal lung
tissues. The association of Tiam1 protein expression with the clinicopathological characteristics and the prognosis of
lung adenocarcinoma were subsequently assessed.
Results: Immunohistochemical analysis showed that 60 of 98 (61.22%) adenocarcinoma tissues showed high
expression of Tiam1, and high Tiam1 expression was significantly associated with advanced TNM stage (P < 0.0005)
and lymph node status (P < 0.0005) of lung adenocarcinoma. Moreover, the lung adenocarcinoma patients with low
Tiam1 expression had higher overall survival than patients with high Tiam1 expression (log rank value = 10.805,
P = 0.001). High expression of Tiam1 predicted poor overall survival of patients in stages I + II (P = 0.006).
Furthermore, multivariate analysis indicated that high expression of Tiam1 protein was an independent
prognostic factor for overall survival (P = 0.011) in patients with lung adenocarcinoma.
Conclusion: These findings suggest for the first time that Tiam1 expression may be beneficial in predicting
lymph node metastasis and survival of patients with lung adenocarcinoma. A future study will investigate
whether Tiam1 can serve as a novel therapeutic target in lung adenocarcinoma.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/1377798917111123.
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Lung cancer is the leading cause of cancer deaths world-
wide. Adenocarcinoma is the most frequent type of lung
cancer, which has a tendency to spread to the lymph
nodes [1]. Currently, although therapy strategies have
improved, the prognosis of lung adenocarcinoma pa-
tients is still poor. The main reason is that many pa-
tients have high frequency of metastasis at diagnosis.* Correspondence: shenhong2010168@163.com
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unless otherwise stated.Identification of molecular targets that contribute to
adenocarcinoma metastasis can help in selecting the best
treatment strategy and improve lung adenocarcinoma
outcomes.
Tiam1, also called T-cell lymphoma invasion and
metastasis-inducing factor, was first identified as a
metastasis-related gene in the aggressive mice T lymph-
oma cells [2]. It is a member of guanine nucleotide ex-
change factors (GEFs) and regulates the guanosine
triphosphatase to facilitate the exchange of guanosine di-
phosphate for guanosine triphosphate. This indicates that
Tiam1 is involved many biological processes by regulating
a variety of GTP-binding proteins. It has been reported
that Tiam1 participates in cytoskeleton rearrangement,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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broblasts and epithelial cells [3-6]. Accumulating evi-
dences have shown that Tiam1 expression plays a role in
cancer progression and metastasis by activating Rho-like
GTPases and Tiam1-Rac1 pathway in various cancers,
such as nasopharyngeal carcinoma [7], breast cancer [8],
colorectal cancer [9], retinoblastoma [10], hepatocellular
carcinoma [11] and Ras-induced skin tumors [12]. More-
over, many studies have shown that Tiam1 expression
might be a new and independent predictor of prognosis in
various solid tumors [13-15]. However, the potential prog-
nostic relevance of Tiam1 expression in lung adenocarcin-
oma has no been investigated.
In this study, we attempted to investigate the expres-
sion of Tiam1 in lung adenocarcinoma using immuno-
histochemical staining and identify its relationship to
lymph node metastasis, prognosis and clinicopathologi-
cal features.
Materials and methods
Patients and tissue samples
Formalin-fixed, paraffin-embedded samples of 98 lung
adenocarcinoma tissue and 30 normal lung tissues were
obtained from surgical patients between 2002 and 2006
from NanFang hospital of Southern Medical University,
Guangzhou, China. Of 98 patients with lung adenocar-
cinoma, there were 53 men and 45 women, between the
ages of 34 and 79 years (median, 57 years). The averageFigure 1 Expression of Tiam1 in lung adenocarcinoma and normal lung
in lung adenocarcinoma tissue; C Moderate expression in lung adenocarcinomsurvival time was 37.7 months for these patients, and
ranged from 1 to 101 months. Lung adenocarcinomas
were graded and staged according to 2009 WHO/IASLC
[16]. Diagnosis was confirmed by the Department of
Pathology of Nan Fang hospital. No patients in this
study had received any adjuvant systemic therapy before
surgery. The Ethics Committee of Southern Medical
University gave prior approval for this study, and every
patient provided written informed consent.
Immunohistochemistry (IHC)
Immunohistochemical study of Tiam1 was performed
on formalin-fixed, paraffin-embedded, 5 μm-thick sec-
tions using Envision method. In brief, the sections were
deparaffinized and dehydrated. Endogenous peroxidase
activity was halted through the administration of 0.3%
hydrogen peroxidase for 10 min. After having been
rinsed in phosphate-buffered saline (PBS), the tissue sec-
tions were processed in a 0.01 M citrate buffer (PH6.0)
and treated with high-pressure antigen retrieval. The
sections were incubated with primary polyclonal anti-
body rabbit anti-Tiam1 (1: 50; Santa Cruz Biotech, USA)
overnight at 4°C. Followed by washing in PBS, the slides
were subsequently incubated with Polymer Helper
(PV9000 kits, Zhongshan Bio Corp., Beijing, China) for
20 min. Then, after washing again with PBS, the sections
were incubated with poly peroxidase-goat-anti-rabbit
IgG antibody (PV9000 kits, Zhongshan Bio Corp., Beijing,tissue. A Negative expression in normal lung tissue; B Mild expression
a tissue; D Strong expression in lung adenocarcinoma tissue.
Figure 2 Kaplan–Meier curves of overall survival defined by
Tiam1 expression. Patients with low Tiam1 expression had higher
overall survival than patients with high Tiam1 expression (P = 0.001,
log rank test).
Table 1 Association of Tiam1 expression with
clinicopathological characteristics from lung adenocarcinoma
Characteristics Cases Low expression High expression P
n (%) n (%)
Age (years)
<60 55 18(33) 37(67)
0.165
≥60 43 20(47) 23(53)
Gender
Male 53 24 (45) 29 (55)
0.151
Female 45 14 (31) 31 (69)
Differentiation
High 39 14 (36) 25 (64)
0.634
Low 59 24 (41) 35 (59)
Tumor size (cm)
≤3 42 19 (45) 23 (55)
0.255
>3 56 19 (34) 37 (66)
TNM stage
I 27 19 (70) 8 (30)
<0.0005
II 26 11 (42) 15 (58)
III 39 7 (18) 32 (82)
IV 6 1 (17) 5 (83)
Lymph node
metastasis
No 39 24 (62) 15 (38)
<0.0005
Yes 59 14 (24) 45 (76)
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nobenzidine (Zhongshan Bio Corp., Beijing, China) at
room temperature for 7 min. Finally, the sections were
counterstained with hematoxylin, dehydrated, cleared, and
mounted. The sections not incubated with primary anti-
body served as negative controls. The sections with con-
firmed positive expression of Tiam1 were used as a
positive control, and only cytoplasmic staining was con-
sidered positive.
Evaluation of immunohistochemical staining
For the assessment, representative areas of each section
were selected, and cells were counted in five fields at 400-
fold magnification. Scores for the percentage of tumor cells
stained positive were as follows: 0, <5%; 1, ≥5 to 25%; 2, >25
to 50%; 3, >50 to 75%; and 4, >75%. Staining intensity was
scored as 0, lack of staining; 1, mild staining; 2, moderate
staining; and 3, strong staining. Based on the semi-
quantitative score calculated by multiplying these two
values (which ranged from 0-12), the stained sections
were defined as either low expression(0–3) or high ex-
pression(≥4). The immunostained slides were assessed
by two independent pathologists, who were blinded to
the clinicopathologic information.
Statistical analysis
Statistical analyses were carried out using the SPSS 13.0
statistical software package. Pearson’s chi-square (×2)
test was used to analyze the association between Tiam1
expression and each clinicopathological parameter. The
survival curves were generated according to the Kaplan–
Meier method, and differences in survival were analyzed
by log-rank test. Survival data were evaluated using uni-
variate and multivariate Cox regression analyses. P value
less than 0.05 was considered statistically significant.
Result
Tiam1 protein expression level was determined by im-
munohistochemistry in 98 lung adenocarcinoma tissues
and 30 non-neoplastic tissues (used as a normal control).
As shown in Figure 1, There was no protein expression
or very weak staining found in normal lung epithelia.
Conversely, the immunoreactive patterns of Tiam1 were
predominantly positively identified in the cancer tissues.
Tiam1 protein was stained clearly brown-yellow and lo-
calized in the cell cytoplasm. Of these tumor tissues,
sixty exhibited high expression (61.22%), and 38 low ex-
pression (38.78%). The correlation between Tiam1 pro-
tein expression and clinicopathological features was
listed in Table 1. Tiam1 protein expression was signifi-
cantly associated with TNM stage (P < 0.0005) and lymph
node status (P < 0.0005), but not with patients’ age, gender,
differentiation and tumor size. Overall survival analysis
using the Kaplan–Meier method showed that patients
Figure 3 Association of Tiam1 expression with overall survival of patients with lung adenocarcinoma in different stages. High
expression of Tiam1 predicted poor overall survival in stages I + II (P = 0.006) but not stages III + IV (P = 0.441) patients (Figure 3A, B).
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patients with high Tiam1 expression (Figure 2; log rank
value = 10.805, P = 0.001). Moreover, expression of Tiam1
predicted poor overall survival in stages I + II (P = 0.006)
but not stages III + IV (P = 0.441) patients (Figure 3A, B).
Upon the univariate analysis with the cox proportional
hazards model, TNM stage (P = 0.013), lymph node status
(P = 0.015) and Tiam1 expression (P = 0.002) were associ-
ated with overall survival. Multivariate analyses revealed
that high expression of Tiam1 was an independent pre-
dictor of an unfavorable prognosis (Hazard ratio, 2.085;
95% CI, 1.186-3.667; P = 0.011; Table 2).
Discussion
Lung adenocarcinoma, a major subtype of non-small-
cell lung carcinomas (NSCLC), is one of the most deadly
human carcinomas, accounting for approximately one
third of all lung cancer cases. Distinguished from lung





Tumor size 1.545 0.956-2.496
Differentiation 1.339 0.824-2.178
TNM stage 1.811 1.136-2.887
Lymph node status 1.842 1.125-3.015
Tim1 expression 2.268 1.367-3.764
Note: 95% CI means 95% confidence interval, HR means Hazard ratio.unique biological and clinical characteristics, such as fre-
quent mutations of epidermal growth factor receptor
and anaplastic lymphoma kinase. Despite advances in
diagnosis and compositive therapy, the overall survival
rate for patients with lung adenocarcinoma is still low.
The main reason of cancer-related mortality is lymph
node metastasis. Therefore, prediction of regional lymph
node status and patient survival is important, because it
can influence the choice of treatment strategies.
Tiam1 was originally identified a metastasis-related
gene of T lymphoma. As one of the guanine nucleotide
exchange factors (GEFs), it was crucially involved in a
variety of tumor signaling pathway through the regula-
tion of Rho GTPases functions. HOU et al. found that
down-regulation of Tiam1 using RNA interference re-
sulted in inhibition of in vitro invasiveness in giant-cell
lung carcinoma cells [17]. Liu et al. reported that Tiam1
gene plays an important role in the proliferation, inva-
sion, and metastasis of colorectal cancer cells [18].ng adenocarcinoma patients
Multivariate
P HR 95% CI P
0.903 0.912 0.566-1.468 0.704
0.727 1.068 0.662-1.724 0.788
0.076 1.247 0.734-2.119 0.415
0.239 1.238 0.732-2.095 0.426
0.013 1.028 0.526-2.011 0.935
0.015 1.300 0.669-2.529 0.439
0.002 2.085 1.186-3.667 0.011
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with motility in human breast cancer cell lines and was
necessary to maintain the motile phenotype [19]. Studies
also showed that up-regulation of Tiam1 was associated
with metastasis of hepatocellular carcinoma [20] and
gastric cancer [21]. These data indicated that Tiam1 ex-
pression can induce invasion and metastasis of tumor
cells. And more notably, high expression of Tiam1 in
tumor cells, implying a poor prognosis, has been ob-
served in several solid tumors. For example, high Tiam1
expression is an independent predictor of decreased
disease-free survival for patients with prostate cancer
[13]. Overexpression of Tiam1 correlates with poor
prognosis in hepatocellular carcinoma [22]. Recently, Du
et al. has suggested that high Tiam1 expression is associ-
ated with poor overall survival in patients with primary
gallbladder carcinoma [23]. Nevertheless, whether these
finding of Tiam1 can be extended to lung adenocarcin-
oma remains elusive.
In this study, we analyzed the expression of Tiam1 in 98
cases of lung adenocarcinoma tissues using immunohisto-
chemistry. We found that Tiam1 expression was upregu-
lated in lung adenocarcinoma compared to normal lung
tissues, which suggest that Tiam1 like other members of
the GEFs family, has an oncogenic role in the tumorigen-
esis of lung adenocarcinoma. Our finding is in consistence
with previous studies that Tiam1 expression was found in
multiple different cancer tissues, confirms a significant re-
lation between Tiam1 expression and genesis and devel-
opment of lung adenocarcinoma.
Our analysis further showed that Tiam1 overexpres-
sion correlates with lymph node metastasis of patients
with lung adenocarcinoma, which suggests that Tiam1
might play an important role in the progression and in-
vasion of lung adenocarcinoma. This result strongly sup-
ports our previous observation that Tiam1 expression
was closely associated with 1ymph node metastasis in
NSCLC [24]. In addition, evidence also suggested that
expression of Tiam1 is closely associated with lymph node
metastasis in other tumor tissues [25,26]. Molecularly,
Tiam1 participates in cytoskeleton reorganization, cell ad-
hesion and cell migration. Thus, we anticipate that Tiam1
may reshape lung cancer cells to make them easier to
spread to the lymph nodes or enhance reciprocity between
tumor and stroma, though the precise molecular mechan-
ism of Tiam1’s action in lung adenocarcinoma remains to
be clarified. These results indicate that Tiam1 expression
in lung adenocarcinoma may be predictive of lymph node
metastasis. With this approach, patients at high risk of
lymph node metastasis could be identified for more ag-
gressive treatment.
In the current study, we are the first to report the prog-
nostic value of Tiam1 expression for patients with lung
adenocarcinoma. According to Kaplan–Meier survivalanalysis, Tiam1 protein expression was found to be in-
versely correlated with patient’s overall survival. Increased
expression of Tiam1 protein was significant predictor of
poor prognosis for patients with lung adenocarcinoma, es-
pecially for patients with stage I-II cancer. Multivariate
analysis revealed a significant negative relationship be-
tween the Tiam1 overexpression and overall survival.
Therefore, we can conclude that Tiam1 serves as a bio-
marker for predicting prognosis of lung adenocarcinoma
patients. Since Tiam1 overexpression can be a new pre-
dictor of poor prognosis of patients in a variety of tumors,
it may be served as a new and independent predictor of
prognosis for patients with lung adenocarcinoma as well.
Yet, due to our limited sample size, with only six patients
of stage IV, the observed association of Tiam1 expression
with pathological stage should be verified by further
studies.
In summary, expression of Tiam1 protein was signifi-
cantly higher in lung adenocarcinoma tissue than in
normal tissue. Higher Tiam1 expression is associated
with lymph node metastasis, and is also an independent
prognostic marker of poor survival in patients with
lung adenocarcinoma. Tiam1 may serve as a useful
molecular marker for lung adenocarcinoma progres-
sion and invasion. However, further studies are needed
to verify our current findings, and we will investigate
whether Tiam1 is a useful therapeutic target in lung
adenocarcinoma.
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